Article
Cancer-Associated SF3B1 Mutations Confer a BRCA-Like Cellular Phenotype and Synthetic Lethality to PARP Inhibitors.
Cancer research - 1 Mar 2022
Lappin Katrina M, Barros Eliana M, Jhujh Satpal S, Irwin Gareth W, McMillan Hayley, Liberante Fabio G, Latimer Cheryl, La Bonte Melissa J, Mills Ken I, Harkin D Paul, Stewart Grant S, Savage Kienan I
Abstract excerpt
Mutations in SF3B1 have been identified across several cancer types. This key spliceosome component promotes the efficient mRNA splicing of thousands of genes including those with crucial roles in the cellular response to DNA damage. Here, we demonstrate that depletion of SF3B1 specifically compromises homologous recombination (HR) and is epistatic with loss of BRCA1. More importantly, the most prevalent...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.